Schistosomiasis mansoni: novel chemotherapy using a cysteine protease inhibitor.
Schistosomiasis is a chronic, debilitating parasitic disease infecting more than 200 million people and is second only to malaria in terms of public health importance. Due to the lack of a vaccine, patient therapy is heavily reliant on chemotherapy with praziquantel as the World Health Organization-...
Main Authors: | Maha-Hamadien Abdulla, Kee-Chong Lim, Mohammed Sajid, James H McKerrow, Conor R Caffrey |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2007-01-01
|
Series: | PLoS Medicine |
Online Access: | http://europepmc.org/articles/PMC1764436?pdf=render |
Similar Items
-
SmCL3, a gastrodermal cysteine protease of the human blood fluke Schistosoma mansoni.
by: Jan Dvorák, et al.
Published: (2009-06-01) -
Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening.
by: Maha-Hamadien Abdulla, et al.
Published: (2009-07-01) -
Update on drug development targeting parasite cysteine proteases.
by: James H McKerrow
Published: (2018-08-01) -
The diverse roles of cysteine proteases in parasites and their suitability as drug targets.
by: James H McKerrow
Published: (2018-08-01) -
Cure of hookworm infection with a cysteine protease inhibitor.
by: Jon J Vermeire, et al.
Published: (2012-01-01)